Trials / Recruiting
RecruitingNCT07335627
Clindamycin as Antimicrobial Treatment for Streptococcus Spp. PeRiprosthetic Infection
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 260 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Clindamycin is an antibiotic with several advantages: high oral bioavailability and good bone and joint penetration. In France, it is a recommended drug for other types of Streptococcus spp. osteoarticular infections and can be used as an alternative to amoxicillin for periprosthetic infections, including when implants are retained. The hypothesis of this study is that clindamycin is no less effective than other drugs commonly used to treat periprosthetic Streptococcus spp. infections. The primary objective of this study is to evaluate the success rate of Streptococcus spp. periprosthetic joint infections treated with clindamycin compared to other antibiotic treatments.
Conditions
Timeline
- Start date
- 2025-02-21
- Primary completion
- 2026-07-01
- Completion
- 2026-07-21
- First posted
- 2026-01-13
- Last updated
- 2026-01-13
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT07335627. Inclusion in this directory is not an endorsement.